

Piergiorgio Cojutti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1021993/publications.pdf>

Version: 2024-02-01

55
papers

1,498
citations

304743

22
h-index

330143

37
g-index

55
all docs

55
docs citations

55
times ranked

1352
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0190821. | 3.2 | 1 |
| 2 | Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clinical Pharmacokinetics, 2022, 61, 505-513. | 3.5 | 2 |
| 3 | Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Critical Care, 2022, . | 5.8 | 41 |
| 4 | Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, . | 3.2 | 28 |
| 5 | Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6" Clinical Pharmacokinetics, 2021, 60, 833-834. | 3.5 | 0 |
| 6 | Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2021, 58, 106408. | 2.5 | 12 |
| 7 | Impact of Maximizing C _{ss} /MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Frontiers in Pharmacology, 2021, 12, 781892. | 3.5 | 12 |
| 8 | Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3029-3037. | 3.0 | 24 |
| 9 | Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa. Pharmaceutics, 2020, 12, 785. | 4.5 | 6 |
| 10 | Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clinical Pharmacokinetics, 2020, 59, 1251-1260. | 3.5 | 25 |
| 11 | Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study. Therapeutic Drug Monitoring, 2020, 42, 349-352. | 2.0 | 7 |
| 12 | Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3588-3595. | 3.0 | 35 |
| 13 | Treatment of <i>Candida</i> infections with fluconazole in adult liver transplant recipients: Is TDM-guided dosing adaptation helpful?. Transplant Infectious Disease, 2019, 21, e131113. | 1.7 | 12 |
| 14 | Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 63 |
| 15 | Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 1648-1655. | 3.0 | 11 |
| 16 | Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. British Journal of Clinical Pharmacology, 2019, 85, 266-269. | 2.4 | 8 |
| 17 | Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. European Journal of Clinical Pharmacology, 2018, 74, 1091-1092. | 1.9 | 5 |
| 18 | Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clinical Pharmacokinetics, 2018, 57, 989-1000. | 3.5 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp.. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1449-1459. | 1.9 | 6 |
| 20 | Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-release tablets in adult patients with haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2544-2550. | 2.4 | 20 |
| 21 | Is meropenem MIC increase against KPC-producing <i>Klebsiella pneumoniae</i> correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 14, 238-241. | 2.2 | 4 |
| 22 | A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 303-308. | 2.5 | 64 |
| 23 | Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 23-28. | 2.5 | 12 |
| 24 | Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing <i>Klebsiella pneumoniae</i> ?. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 255-258. | 2.5 | 65 |
| 25 | Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 44 |
| 26 | Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2342-2350. | 3.0 | 26 |
| 27 | A 1-year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 341-348. | 2.4 | 18 |
| 28 | Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderl. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1070-1078. | 1.9 | 24 |
| 29 | Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450 (CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 474-479. | 2.5 | 34 |
| 30 | Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1459-1463. | 3.2 | 17 |
| 31 | Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1323-1329. | 3.0 | 13 |
| 32 | Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. <i>Transplant Infectious Disease</i> , 2015, 17, 926-928. | 1.7 | 6 |
| 33 | Risk factors associated with the onset of daptomycin non-susceptibility in <i>Staphylococcus aureus</i> infections in critically ill patients. <i>Intensive Care Medicine</i> , 2015, 41, 366-368. | 8.2 | 13 |
| 34 | Pharmacokinetics and Pharmacodynamics of Continuous-Infusion Meropenem in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5535-5541. | 3.2 | 16 |
| 35 | Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. <i>Clinical Pharmacokinetics</i> . 2015. 54. 933-941. | 3.5 | 31 |
| 36 | Linezolid underexposure in a patient co-treated with venlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1285-1286. | 1.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolated from patients with bloodstream infections in Northeast Italy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 53-56. | 1.8 | 5 |
| 38 | Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 198-206. | 3.0 | 33 |
| 39 | <i>Drugs and Blood Cells.</i> , 2015, , 111-147. | | 0 |
| 40 | Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 570-571. | 2.5 | 7 |
| 41 | Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 674-676. | 2.0 | 26 |
| 42 | Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening <i>Staphylococcus aureus</i> -complicated skin and soft tissue infection associated with bacteraemia. <i>Infection</i> , 2014, 42, 207-210. | 4.7 | 18 |
| 43 | Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2585-2586. | 3.0 | 23 |
| 44 | Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 432-437. | 2.5 | 5 |
| 45 | Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥ 40 kg/m ²) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring. <i>Clinical Pharmacokinetics</i> , 2014, 53, 753-762. | 3.5 | 33 |
| 46 | Gentamicin once-daily in enterococcal endocarditis. <i>International Journal of Cardiology</i> , 2013, 168, 5033-5034. | 1.7 | 12 |
| 47 | Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: Dose Intensification Coupled with Avoidance of Proton Pump Inhibitors Is Beneficial in Shortening Time to Effective Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6081-6084. | 3.2 | 23 |
| 48 | Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2034-2042. | 3.0 | 208 |
| 49 | Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6343-6348. | 3.2 | 76 |
| 50 | Successful Long-Term Treatment of Cerebral Nocardiosis with Unexpectedly Low Doses of Linezolid in an Immunocompromised Patient Receiving Complex Polytherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3438-3440. | 3.2 | 24 |
| 51 | Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment of Experimental Endocarditis Due to Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4496-4497. | 3.2 | 2 |
| 52 | TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1022-1022. | 1.9 | 52 |
| 53 | Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4605-4610. | 3.2 | 172 |
| 54 | Validation of Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure During the First Year After Heart Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 4277-4284. | 0.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Pharmacokinetic Interaction Between Everolimus and Antifungal Triazoles in a Liver Transplant Patient. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1711-1716. | 1.9 | 27 |